Epigenomics AG (FRA:ECX)
€ 1.4 0.4 (40%) Market Cap: 1.23 Mil Enterprise Value: -2.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

Epigenomics AG - Special Call Transcript

Nov 21, 2019 / 02:00PM GMT
Release Date Price: €218.3 (+3.36%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Epigenomics conference call regarding today's presentation, quantifying the impact of adherence to screening on colorectal cancer incidence and mortality. (Operator Instructions)

Now I hand the floor over to Frederic Hilke.

Frederic Hilke
Epigenomics AG - IR Officer

Thank you very much. Hello, and welcome to the conference call with Dr. D'Andrea and Dr. Najafzadeh, the lead and senior author, respectively, of the soon-to-be published manuscript describing a new microsimulation model on CRC screening strategies. Both are with me on the line to discuss today's presentation at the 12th European Public Health Conference entitled, quantifying the impact of adherence to screening on colorectal cancer incidence and mortality.

Dr. Elvira D'Andrea received her medical degree and completed a residency in Public Health and Preventive Medicine at Sapienza University of Rome in Italy. She then completed a Master of Public Health in Quantitative Methods at Harvard T.H. Chan School of Public Health

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot